The 9A2 monoclonal antibody specifically binds to Oct-2 that has a molecular weight of approximately 50-60 kDa. The 9A2 antibody was generated against the 44 N-terminal amino acids common to mouse Oct-2 isoforms and crossreacts with both human and mouse Oct-2. Oct-2 is a POU class 2 homeobox 2 transcription factors (POU2F2) that is also known as OCT2, OTF2, Lymphoid-restricted immunoglobulin octamer-binding protein NF-A2 and Octamer-binding transcription factor 2. The POU domain in the Oct-2 protein is required for low and high affinity cooperative binding of the octomer sequence and heptamer site in immunoglobulin promoters and promoters for other genes. Oct-2 is expressed in B cells, activated CD4+ and CD8+ T cells, monocytes/macrophages and subsets of dendritic cells. Oct-2 is reportedly associated with neoplasms including Diffuse Large B-cell lymphoma and Nodular Lymphocyte predominant Hodgkin's lymphoma. Studies with knockout mouse models suggest Oct-2 is required for B cell maturation, but not for B cell commitment, and for B cell production of IL-6. Multiparameter Analyses of Oct-2 Expression: Panel 1: Human peripheral blood mononuclear cells, PBMCs, were fixed and permeabilized with BD Pharmingen™ Transcription Factor Buffer Set. Cells were then stained with Purified Rat IgG2a, κ Isotype Control or Purified Rat Anti-Oct-2 and followed with PE Mouse Anti-Rat IgG2a. Prior to fixation, PBMCs were stained with Pacific Blue™ Anti-Human CD3, APC Anti-Human CD19 and FITC Anti-Human CD14. The target event acquisition stop count was 5,000 CD19+ B cells. Two-color flow cytometric data were derived from gated events with the light-scatter characteristics and positive staining for CD3+ T cells (labeled T), CD14+ monocytes (M) or CD19+ B lymphocytes (B). Flow cytometry was performed using a BD LSRFortessa™ Cell Analyzer. Panels 2a, 2b: BALB/c mouse splenocytes and lymph node cells were similarly fixed, permeabilized and stained for Oct-2 as described. After washing, cells were stained with Alexa Fluor® 647 Anti-Mouse CD45R/B220 and FITC Anti-Mouse CD3e and analyzed. Panel 3a: Western blot of Oct-2 expressed by human (Raji, HL-60, or PBMC) or mouse (thymus, spleen) cells. Lysates (20 μg protein/lane) were blotted using Anti-Oct-2, HRP Anti-Rat Ig (Southern Biotech, 3030-05) followed by development with Pierce HRP Substrate (Cat. No. 34080). Oct-2 was identified as a protein band of ~50-60 kDa. Panel 3b: Immunohistochemical analysis of tonsillar Oct-2 expression. Paraffin-embedded tissue sections (5 μm) on poly-l-lysine treated slides were dewaxed, rehydrated and heated (3 min) in TRIS-EDTA 0.01M (pH 9) to retrieve antigen. After cooling, slides were placed in TBS (5 min). Endogenous peroxidase was blocked with a peroxidase-block reagent (DAKO, Denmark). Slides were incubated (30 min, RT) with Anti-Oct-2 antibody. Binding was detected by the peroxidase-based EnVision+ method and sections were stained with hematoxylin. Data was reproduced with the permission of The Walter and Eliza Hall Institute of Medical Research. 562837 Rev. 1 Page 1 of 2
BD Pharmingen™ Purified Rat Anti-Oct-2 - Purified - Clone 9A2 - Isotype Rat IgG2a, κ - Reactivity Ms, Hu - 50 μg
Purification
The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C
Storage Comment
Store undiluted at 4°C.
Boreström, Forsman, Rüetschi, Rymo: "E2F1, ARID3A/Bright and Oct-2 factors bind to the Epstein-Barr virus C promoter, EBNA1 and oriP, participating in long-distance promoter-enhancer interactions." in: The Journal of general virology, Vol. 93, Issue Pt 5, pp. 1065-75, (2012) (PubMed).
Karnowski, Chevrier, Belz, Mount, Emslie, DCosta, Tarlinton, Kallies, Corcoran: "B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1." in: The Journal of experimental medicine, Vol. 209, Issue 11, pp. 2049-64, (2012) (PubMed).
Saglam, Uner: "Immunohistochemical expression of Mum-1, Oct-2 and Bcl-6 in systemic anaplastic large cell lymphomas." in: Tumori, Vol. 97, Issue 5, pp. 634-8, (2011) (PubMed).
Corcoran, Koentgen, Dietrich, Veale, Humbert: "All known in vivo functions of the Oct-2 transcription factor require the C-terminal protein domain." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 172, Issue 5, pp. 2962-9, (2004) (PubMed).
Browne, Petrosyan, Hernandez, Chan: "The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma." in: American journal of clinical pathology, Vol. 120, Issue 5, pp. 767-77, (2003) (PubMed).
Kang, Tsang, Doll, Scherle, Ko, Tran, Lenardo, Staudt: "Induction of the POU domain transcription factor Oct-2 during T-cell activation by cognate antigen." in: Molecular and cellular biology, Vol. 12, Issue 7, pp. 3149-54, (1992) (PubMed).
Target
Oct-2 (POU2F2)
(POU domain, class 2, transcription factor 2 (POU2F2))